Posted by Michael Wonder on 04 Mar 2020
Sanofi, fighting back in insulin price debate, says its net prices fell 11%
4 March 2020 - Politicians have called price increases egregious, while large insulin makers have become prime targets for criticism in the presidential race.
Sanofi, maker of the world’s bestselling insulin, said the price it received for its drugs fell on average just over 11% last year, including discounts it pays to insurers and health pharmacy-benefit managers.
It is the latest in a series of drug company pricing disclosures aimed at trying to share the blame for rising health-care costs. Insulin, in particular, has become a political lightning rod in the drug-price debate.
